Vyome Showcases Transformative Phase 2 Clinical Results for VT-1953 at AACR 2026 Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biotechnology company focused on developing innovative therapies for underserved conditions, has unveiled comprehensive Phase 2 investigator-initiated study results along with supporting…
Veristat to Acquire Certara’s Regulatory Affairs and Medical Writing Business Veristat, a science-first, full-service clinical research organization (CRO) and consultancy specializing in advancing complex therapies from early development through regulatory submission, has announced its intended acquisition of Certara’s Regulatory and…
CareDx to Present Over 50 Abstracts, Including 16 Oral Presentations, at ISHLT 46th Annual Meeting CareDx, a leading precision medicine organization dedicated to advancing transplant care through innovative diagnostic and digital health solutions, has announced its participation in the International…
Donor Funding Drives $15M Initiative Supporting 62 Researchers Focused on Alzheimer’s, Macular Degeneration, and Glaucoma The BrightFocus Foundation has announced a major new investment of $15.2 million in research grants aimed at advancing scientific discovery in three of the most…
U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus Genentech, a member of the Roche Group, has announced a major regulatory milestone in its efforts to expand treatment options for autoimmune diseases.…
Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision oncology subsidiary, Ignite Proteomics. The subsidiary has been featured in…
Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it will showcase its proprietary nPulse™ platform and present new clinical…
Akamis Bio Reports Promising Early Findings from Phase 1b FORTRESS Trial of NG-350A in MMR-Proficient Locally Advanced Rectal Cancer Akamis Bio, a biotechnology company focused on transforming the treatment landscape for colorectal cancer, has reported encouraging early clinical data from…
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season Merck & Co.—known as MSD outside the United States and Canada—has announced a major regulatory…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At the ESCMID Global 2026, Bruker Corporation unveiled a wide-ranging set of portfolio enhancements spanning microbial identification, outbreak surveillance, and reflex next-generation sequencing (NGS) workflows. These updates…
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home…
Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S. launch of Sdamlo™ (amlodipine for…